Q3 Earnings Estimate for CNTA Issued By Leerink Partnrs

Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) - Investment analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Centessa Pharmaceuticals in a report issued on Monday, March 24th. Leerink Partnrs analyst D. Risinger expects that the company will earn ($0.40) per share for the quarter. The consensus estimate for Centessa Pharmaceuticals' current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals' FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.71) EPS, FY2027 earnings at ($1.84) EPS, FY2028 earnings at ($2.06) EPS and FY2029 earnings at $0.49 EPS.

A number of other research analysts have also recently weighed in on CNTA. Guggenheim reaffirmed a "buy" rating and set a $28.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and issued a $27.00 price target on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Piper Sandler initiated coverage on shares of Centessa Pharmaceuticals in a research report on Monday. They set an "overweight" rating and a $38.00 price objective on the stock. Finally, TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a "buy" rating for the company. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus target price of $27.71.

Remove Ads

Centessa Pharmaceuticals Stock Performance

CNTA traded down $0.52 during trading on Thursday, hitting $14.07. The company's stock had a trading volume of 326,115 shares, compared to its average volume of 547,445. The business's 50 day simple moving average is $16.48 and its 200-day simple moving average is $16.44. The firm has a market cap of $1.86 billion, a PE ratio of -9.19 and a beta of 1.54. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.38) by $0.04.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several large investors have recently added to or reduced their stakes in CNTA. Price T Rowe Associates Inc. MD raised its holdings in Centessa Pharmaceuticals by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock valued at $89,854,000 after buying an additional 685,371 shares during the period. Adage Capital Partners GP L.L.C. grew its stake in shares of Centessa Pharmaceuticals by 22.0% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock valued at $85,744,000 after buying an additional 924,027 shares during the last quarter. Janus Henderson Group PLC lifted its stake in shares of Centessa Pharmaceuticals by 279.2% during the 4th quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company's stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC lifted its stake in shares of Centessa Pharmaceuticals by 24.3% during the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company's stock worth $58,603,000 after acquiring an additional 684,391 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its holdings in Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company's stock valued at $57,396,000 after acquiring an additional 710,936 shares during the period. 82.01% of the stock is owned by institutional investors.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider David M. Chao sold 7,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $17.17, for a total transaction of $120,190.00. Following the completion of the transaction, the insider now owns 225,007 shares in the company, valued at $3,863,370.19. This trade represents a 3.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of Centessa Pharmaceuticals stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $15.29, for a total transaction of $91,740.00. Following the completion of the transaction, the general counsel now directly owns 118,265 shares of the company's stock, valued at $1,808,271.85. The trade was a 4.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 260,168 shares of company stock valued at $4,309,568. 11.59% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.